List view / Grid view
For those that hoped artificial intelligence would help to deliver drugs that actually work, the hope lives on. Here, Dr Raminderpal Singh reflects on the sobering reality check that 2025 delivered to the industry.
Scientists have developed a lab-made antibody that targets a sugar found only on bacterial cells, successfully clearing deadly, drug-resistant infections in mice.
Radiopharmaceuticals are emerging as a development platform rather than a single modality in oncology. This article explores what that means for cancer drug development and how integrated strategies can reduce risk and accelerate progress to the clinic.
Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
Scientists have discovered a hidden RNA ‘switch’ used by bacteriophages to hijack bacterial cells, revealing a new layer of viral control that could help advance phage therapy and efforts to combat antibiotic-resistant infections.
Great biologics don’t happen by chance, and neither do great STEM careers. Dr Lidia Serina shares the lessons behind both.
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
Scientists at the University of Washington’s Institute for Protein Design have used artificial intelligence to create antibodies entirely from scratch, a breakthrough that could reshape drug discovery.
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
6 October 2025 | By
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
